What's Going On With Hoth Therapeutics Stock?

Hoth Therapeutics Inc HOTH shares are trading higher Monday after the company announced positive BioLexa Phase 1b clinical trial results.

BioLexa met the primary and secondary endpoints for safety and efficacy in a Phase 1b clinical trial in adult patients with mild-to-moderate atopic dermatitis. A clinically relevant reduction in the total body surface area affected by atopic dermatitis was observed in 71% patients treated with BioLexa.

"Today's positive results give us even more confidence that BioLexa can help provide relief from atopic dermatitis in patients, without the harmful long-term effects of corticosteroids and other side effects that many patients suffer with today's choice of approved therapeutics," said Robb Knie, CEO of Hoth Therapeutics.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful and ground-breaking treatments with a goal to improve patient quality of life. 

See Also: What's Going On With Apple Shares

HOTH Price Action: Hoth Therapeutics has a 52-week high of $43.75 and a 52-week low of $5.61.

The stock was up 30.7% at $7.43 at time of publication, according to Benzinga Pro.

Photo: StockSnap from Pixabay.